Blood thinner study targets dosing mystery in obesity and bariatric patients

NCT ID NCT04180436

Completed Knowledge-focused Sponsor: University Hospital, Brest Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how the blood thinner rivaroxaban behaves in people with severe obesity or after bariatric surgery (gastric bypass or sleeve gastrectomy). Researchers gave 67 participants rivaroxaban daily for 8 days and measured drug levels and blood clotting. The goal is to understand if obesity or surgery changes how the drug works, which could help doctors choose safer doses.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rivaroxaban (a blood thinner)
What this could lead to: If successful, this study could help doctors adjust blood thinner doses for people with severe obesity or after weight-loss surgery, reducing clot risk.
What could go wrong: This is a small, early-phase study focused on drug levels, not on preventing clots or bleeding. Results may not change practice without larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BARIATRIC SURGERY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

morbid obesity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BARIATRIC SURGERY MORBID OBESITY

Contacts and locations

Locations

CHRU de Brest

Brest, France, 29609, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.